Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy - Trial NCT06379256
Access comprehensive clinical trial information for NCT06379256 through Pure Global AI's free database. This phase not specified trial is sponsored by Chang Gung Memorial Hospital and is currently Not yet recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 300 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Chang Gung Memorial Hospital
Timeline & Enrollment
N/A
Apr 26, 2024
Mar 17, 2032
Primary Outcome
Progression free survival (PFS)
Summary
Radiation therapy (RT) is a highly effective modality for managing localized solid tumors and
 has become a fundamental component of treating unresectable hepatocellular carcinoma (HCC).
 Our previous preclinical investigation (Hsieh et al., Science Immunology 2022) revealed that
 RT can initiate immunogenic cell death and facilitate the cross-presentation of tumor
 antigens by antigen-presenting cells, thereby augmenting systemic anti-tumor T cell responses
 in murine tumor models. However, this immune response subsequent to irradiation has not been
 comprehensively evaluated in clinical trials involving HCC patients. Given that RT represents
 a standard therapeutic approach for unresectable HCC, our ongoing phase II non-randomized
 trial aims to prospectively assess immunological responses and dose-volumetric parameters,
 while identifying predictors of clinical outcomes in patients undergoing definitive RT for
 HCC.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06379256
Non-Device Trial